33620 Results

People

  1. Ladanyi
    Ladanyi
  2. Giralt
    Giralt
  3. Motzer
    Motzer
  4. Reuter
    Reuter
  5. Perales
    Perales
  6. Scher
    Scher
  7. Zelenetz
    Zelenetz
  8. Berger
    Berger
  9. Al-Ahmadie
    Al-Ahmadie
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)
  7. Department of Pathology and Laboratory Medicine (5172)
  8. Surgery (4871)
  9. Sloan Kettering Institute Faculty (3826)
  10. Sloan Kettering Institute Postdocs (3612)
  1. "Meeting abstract"
Formats
  1. Meeting Abstract (33620)
Groups
  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)

More Groups

People
  1. Marc Ladanyi (641)
  2. Sergio Giralt (632)
  3. Robert Motzer (574)
  4. Victor Reuter (568)
  5. Miguel-Angel Perales (482)
  6. Howard Scher (463)

More People

Years
  1. 2025 (295)
  2. 2024 (1694)
  3. 2023 (1954)
  4. 2022 (2196)
  5. 2021 (1731)
  6. 2020 (1901)

More Years

Publications
  1. Journal of Clinical Oncology (6252)
  2. Blood (3939)
  3. Laboratory Investigation (1846)
  4. Cancer Research (1822)
  5. International Journal of Radiation Oncology, Biology, Physics (1643)
  6. Modern Pathology (1494)

More Publications

Publishers
  1. American Society of Clinical Oncology (6251)
  2. Elsevier Inc. (4694)
  3. American Society of Hematology (3939)
  4. American Association for Cancer Research (3045)
  5. Nature Publishing Group (2151)
  6. Oxford University Press (2096)

More Publishers

Results (33620)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase II trial of IDO-inhibitor, BMS-986205 (IDO), and PD-1 inhibitor, nivolumab (NIVO), in recurrent or persistent endometrial cancer (EC; CA017-056)
    Meeting Abstract

    Kyi, C.; Rubinstein, M. M.; Shah, P.; Zhou, Q.; Iasonos, A.; Liu, Y.; Ramirez, L.; Paroder, V.; Green, A.; Friedman, C. F.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Comparative effectiveness of teclistamab versus real-world treatments for patients with triple-class exposed (TCE), relapsed/refractory multiple myeloma (RRMM)
    Meeting Abstract

    Krishnan, A. Y.; Nooka, A. K.; Chari, A.; Garfall, A. L.; Martin, T. G.; Nair, S.; Lin, X. W.; Qi, K. Q.; Londhe, A.; Pei, L. X.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Myeloma developing regimens using genomics (MyDRUG) trial: Results from the RAS mutation targeting arm
    Meeting Abstract

    Kumar, S.; Bianchi, G.; Biran, N.; Hultcrantz, M.; Richter, J. R.; Vij, R.; Ye, J. C.; Zonder, J. A.; DiLello, L.; Yesil, J.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Ethical challenges with CAR T slot allocation with idecabtagene vicleucel manufacturing access
    Meeting Abstract

    Kourelis, T.; Bansal, R.; Patel, K. K.; Berdeja, J. G.; Raje, N. S.; Alsina, M.; Cohen, A. D.; Siegel, D. S. D.; Mailankody, S.; Htut, M.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Effectiveness of adjuvant chemoradiotherapy for oral cavity squamous cell carcinoma with minor and major extranodal extension: A multi-institutional consortium study
    Meeting Abstract

    Kolarski, M. M.; Su, J.; Weinreb, I.; Perez-Ordonez, B.; Patel, S. G.; Valero, C.; Xu, B.; Katabi, N.; Clark, J.; Low, T. H. H.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Quality-adjusted time without symptoms or toxicities (Q-TWiST) analysis of ZUMA-7, a randomized controlled trial of axicabtagene ciloleucel versus standard of care for second-line large B-cell lymphoma
    Meeting Abstract

    Kersten, M. J.; Qiao, Y.; Shah, R.; Solem, C.; Snider, J.; To, C. A.; Cheng, P.; Spooner, C.; Perales, M. A.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Lymphedema therapy referral is associated with improved understanding of lymphedema prevention among breast cancer survivors
    Meeting Abstract

    Klugman, M.; Patil, S.; Finik, J.; Kuo, T. T.; Eberle, C. E.; Pinkhasov, A. M.; Gillis, T.; Gany, F.; Blinder, V. S.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Gene expression of vitamin D (VitD) pathway markers and survival in patients (Pts) with metastatic colorectal cancer (mCRC): CALGB/SWOG 80405 (Alliance)
    Meeting Abstract

    Kohn, C. G.; Ou, F. S.; Ma, C.; Larson, N. B.; Zemla, T. J.; Yuan, C.; Niedzwiecki, D.; Hollis, B. W.; Nixon, A. B.; Lenz, H. J.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Subclonal somatic copy number alterations emerge and dominate in recurrent osteosarcoma
    Meeting Abstract

    Kinnaman, M. D.; Zaccaria, S.; Makohon-Moore, A.; Gundem, G.; Ossa, J. E. A.; Bouvier, N.; Dela Cruz, F. S.; Hameed, M.; Bender, J. L. G.; Tap, W. D.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • A robust, trial-agnostic gene signature for response to tyrosine kinase inhibition in ccRRCC
    Meeting Abstract

    Khaleel, S. S.; Liu, M.; Kuo, F.; Kotecha, R.; Lee, C. H.; Voss, M. H.; Motzer, R. J.; Hakimi, A. A.; Reznik, E.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save